| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a0e4c112c42f7a155a467679cf99e67c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59ec37318623e42970ac9b8cc9e49559 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3829917d997caaac65def42013caf879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbc1674283a8abea9e4bed38a990ec7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb912d639baa486b32927f4c7f342464
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f2031e11cf062c36d63c880495910b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3705de52cacef61f472e34bd2db26b03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eb1f63f26e870932a7c37db91155b51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a619c983df6432ce669affa6bd4680bd |
| publicationDate |
2022-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022200303-A1 |
| titleOfInvention |
Methods for the diagnosis and treatment of t cell-lymphomas |
| abstract |
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11692038-B2 |
| priorityDate |
2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |